Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer

New England Journal of Medicine - Tập 378 Số 2 - Trang 113-125 - 2018
Jean‐Charles Soria1, Yuichiro Ohe2, Johan Vansteenkiste3, Thanyanan Reungwetwattana4, Busyamas Chewaskulyong5, Ki Hyeong Lee6, Arunee Dechaphunkul7, Fumio Imamura8, Naoyuki Nogami9, Takayasu Kurata10, Isamu Okamoto11, Caicun Zhou12, Byoung Chul Cho13, Ying Cheng14, Eun Kyung Cho15, Pei Jye Voon16, David Planchard1, Wu‐Chou Su17, Jhanelle E. Gray18, Siow Ming Lee19, Rachel Hodge20, Marcelo Marotti20, Yuri Rukazenkov20, Suresh S. Ramalingam21
1Gustave Roussy Cancer Campus and University Paris-Sud, Orsay, France
2Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo
3Respiratory Oncology Unit, University Hospital KU Leuven, Leuven, Belgium
4Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok
5Oncology Unit, Department of Medicine, Chiang Mai University, Chiang Mai
6Division of Medical Oncology, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheong-ju
7Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai
8Department of Thoracic Oncology, Osaka International Cancer Institute
9Osaka, the Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama
10Department of Thoracic Oncology, Kansai Medical University Hospital
11Research Institute for Diseases of the Chest, Graduate School of Medical Science, Kyushu University, Fukuoka
12Pulmonary Hospital of Tongji University, Shanghai
13Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul
14Jilin Provincial Cancer Hospital, Changchun
15Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon
16Hospital Umum Sarawak, Kuching, Malaysia
17National Cheng Kung University, Tainan, Taiwan
18Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
19Cancer Research UK Lung Cancer Centre of Excellence, London
20AstraZeneca, Cambridge
21Emory University School of Medicine, Winship Cancer Institute, Atlanta

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1200/JCO.2017.74.6065

10.1093/annonc/mdw326

10.1016/S1470-2045(11)70393-X

10.1056/NEJMoa0810699

10.1200/JCO.2012.44.2806

10.1093/jnci/djw279

10.1016/S1470-2045(09)70364-X

10.1056/NEJMoa0909530

10.1016/S1470-2045(11)70184-X

10.1093/annonc/mdv270

10.1158/1078-0432.CCR-10-2692

10.1158/1078-0432.CCR-12-2246

10.1158/2159-8290.CD-14-0337

10.1200/JCO.2017.35.15_suppl.9005

10.1056/NEJMoa1612674

10.1016/S1470-2045(16)30508-3

10.1200/JCO.2016.70.3223

10.1158/1078-0432.CCR-16-0399

10.1016/j.jtho.2016.11.514

10.1158/0008-5472.CAN-14-3167

10.1158/1535-7163.MCT-14-0723

10.1200/JCO.2017.74.7576

10.1016/S1470-2045(16)30033-X

10.1200/JGO.2016.003392

10.1016/j.lungcan.2012.05.092

10.1158/1078-0432.CCR-12-0357

10.1016/S1470-2045(17)30608-3

Stewart EL, Tan SZ, Liu G, Tsao MS. Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations — a review. Transl Lung Cancer Res 2015;4:67-81.25806347

10.1038/nm.3854

10.1016/j.jtho.2016.12.024

10.1097/JTO.0000000000000688

10.1093/annonc/mdv319

10.2147/OTT.S134382

Thông tin
Thông tin xuất bản

New England Journal of Medicine

Tập 378 Số 2

113-125

Thông tin tác giả